What does this research mean for the field?

The combination of venetoclax and pentostatin elicits a clinical response in patients with T-cell prolymphocytic leukemia (T-PLL). Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 30, 2019Leukemia & lymphoma/Leukemia and lymphomaOpen Access

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

View Full Paper

Ask AI

Bookmark

Abstract

T-cell prolymphocytic leukemia is a postthymic mature lymphoid leukemia known to be associated with poor outcome. The median age at diagnosis is 61 years, and the clinical picture includes high whi...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alfayez et al. (2019) studied this question.

synapsesocial.com/papers/6a61656dec10dc681a0a3086 https://doi.org/10.1080/10428194.2019.1660967

View Full Paper

Ask AI

Bookmark

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

Abstract

Discussion

Cite This Study

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading